Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 34, Issue 11, pp 1507–1513 | Cite as

Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS

  • Deepika GargEmail author
  • Richard Grazi
  • Geralyn M. Lambert-Messerlian
  • Zaher Merhi
Reproductive Physiology and Disease

Abstract

Purpose

The pro-inflammatory advanced glycation end products (AGEs) and their anti-inflammatory soluble receptors, sRAGE, play a role in the pathogenesis of PCOS. There is a correlation between vitamin D (vit D) and sRAGE in the serum, whereby vit D replacement increases serum sRAGE levels in women with PCOS, thus incurring a protective anti-inflammatory role.

Objective

This study aims to compare levels of sRAGE, N-carboxymethyl-lysine (CML; one of the AGEs), and 25-hydroxy-vit D in the follicular fluid (FF) of women with or without PCOS, and to evaluate the correlation between sRAGE and 25-hydroxy-vit D in the FF.

Material and methods

Women with (n = 12) or without (n = 13) PCOS who underwent IVF were prospectively enrolled.

Results

Women with PCOS had significantly higher anti-Mullerian hormone levels, higher number of total retrieved and mature oocytes, and higher number of day 3 and day 5 embryos formed. Compared to women without PCOS, women with PCOS had significantly lower FF sRAGE levels. In women with PCOS, in women without PCOS, and in all participants together, there was a significant positive correlation between sRAGE and 25-hydroxy-vit D. sRAGE positively correlated with CML in women without PCOS but not in women with PCOS.

Conclusions

In women with PCOS, the low ovarian levels of the anti-inflammatory sRAGE suggest that sRAGE could represent a biomarker and a potential therapeutic target for ovarian dysfunction in PCOS. Whether there is a direct causal relationship between sRAGE and vit D in the ovaries remains to be determined.

Keywords

PCOS Advanced glycation end products RAGE sRAGE Vitamin D 

Abbreviations

AGEs

Advanced glycation end products

sRAGE

Soluble receptor for advanced glycation end products

Notes

Acknowledgements

We would like to thank Dr. Bharati Kalgi M.D., Grace Woo, and Dr. Rosine Rosanel M.D. in helping us collect the specimens for the study.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

Grant from Ferring Pharmaceuticals Inc. to Z.M and grant from Genesis Foundation to D.G.

References

  1. 1.
    Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001;16:2606–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Rajani S, Chattopadhyay R, Goswami SK, Ghosh S, Sharma S, Chakravarty B. Assessment of oocyte quality in polycystic ovarian syndrome and endometriosis by spindle imaging and reactive oxygen species levels in follicular fluid and its relationship with IVF-ET outcome. J Hum Reprod Sci. 2012;5:187–93.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012;97:2231–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Garg D, Merhi Z. Advanced glycation end products: link between diet and ovulatory dysfunction in PCOS? Nutrients. 2015;7:10,129–44.CrossRefGoogle Scholar
  8. 8.
    Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl). 2007;85:1413–20.CrossRefGoogle Scholar
  9. 9.
    Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005;1:93–106.CrossRefPubMedGoogle Scholar
  10. 10.
    Uribarri J, del Castillo MD, de la Maza MP, Filip R, Gugliucci A, Luevano-Contreras C, et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr. 2015;6:461–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rutkowska AZ, Diamanti-Kandarakis E. Do advanced glycation end products (AGEs) contribute to the comorbidities of polycystic ovary syndrome (PCOS)? Curr Pharm Des. 2016;22:5558–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Diamanti-Kandarakis E, Piouka A, Livadas S, Piperi C, Katsikis I, Papavassiliou AG, et al. Anti-Mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol. 2009;160:847–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007;127:581–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Garg D, Merhi Z. Relationship between advanced glycation end products and steroidogenesis in PCOS. Reprod Biol Endocrinol. 2016;14:71.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond). 2009;116:621–37.CrossRefGoogle Scholar
  16. 16.
    Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2005;62:37–43.CrossRefGoogle Scholar
  17. 17.
    Wang B, Hao M, Yang Q, Li J, Guo Y. Follicular fluid soluble receptor for advanced glycation end products (sRAGE): a potential protective role in polycystic ovary syndrome. J Assist Reprod Genet. 2016;33:959–65.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Schmidt AM. Soluble RAGEs—prospects for treating & tracking metabolic and inflammatory disease. Vasc Pharmacol. 2015;72:1–8.CrossRefGoogle Scholar
  19. 19.
    Wang B, Li J, Yang Q, Zhang F, Hao M, Guo Y. Decreased levels of sRAGE in follicular fluid from patients with PCOS. Reproduction. 2017;153:285–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Liao Y, Huang R, Sun Y, Yue J, Zheng J, Wang L, et al. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients. Reprod Biol Endocrinol. 2017;15:9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Merhi Z, Irani M, Doswell AD, Ambroggio J. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99:E226–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonetti TC, Borges E Jr, Braga DP, Iaconelli A Jr, Kleine JP, Silva ID. Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction. Reprod BioMed Online. 2013;26:62–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77:343–50.CrossRefGoogle Scholar
  24. 24.
    Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2006;114:577–83.CrossRefPubMedGoogle Scholar
  25. 25.
    Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280:559–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, et al. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:965–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Investig. 2010;33:234–8.CrossRefGoogle Scholar
  28. 28.
    Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014;99:E886–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Revised 2003 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19–25.Google Scholar
  30. 30.
    Gonzalez F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1508–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end products: a link between metabolic and endothelial dysfunction in polycystic ovary syndrome? Metabolism. 2015;64:1564–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod. 2014;29:135–45.CrossRefPubMedGoogle Scholar
  33. 33.
    Diamanti-Kandarakis E, Piperi C, Livadas S, Kandaraki EA, Papageorgiou E, Koutsilieris M: Interference of AGE-RAGE signaling with steroidogenic enzyme action in human ovarian cells. In Ovarian & Uterine Function I. SUN-556-SUN-556.Google Scholar
  34. 34.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.CrossRefPubMedGoogle Scholar
  35. 35.
    Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79:1397–405.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008;294:F1059–64.CrossRefPubMedGoogle Scholar
  38. 38.
    Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Investig. 2008;38:548–54.CrossRefGoogle Scholar
  39. 39.
    Lee TW, Kao YH, Lee TI, Chang CJ, Lien GS, Chen YJ. Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts. Int J Cardiol. 2014;173:236–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Guo YX, He LY, Zhang M, Wang F, Liu F, Peng WX. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Abeta1-40 brain-to-blood efflux and peripheral uptake transport. Neuroscience. 2016;322:28–38.CrossRefPubMedGoogle Scholar
  41. 41.
    Salum E, Kals J, Kampus P, Salum T, Zilmer K, Aunapuu M, et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Diabetes Res Clin Pract. 2013;100:243–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Sung JY, Chung W, Kim AJ, Kim HS, Ro H, Chang JH, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013;230:59–66.CrossRefPubMedGoogle Scholar
  43. 43.
    Sebekova K, Sturmer M, Fazeli G, Bahner U, Stab F, Heidland A. Is vitamin D deficiency related to accumulation of advanced glycation end products, markers of inflammation, and oxidative stress in diabetic subjects? Biomed Res Int. 2015;2015:958097.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102:460–468.e463.CrossRefPubMedGoogle Scholar
  45. 45.
    Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, et al. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J. 2012;164:742–749.e743.CrossRefPubMedGoogle Scholar
  46. 46.
    Kerkeni M, Saidi A, Bouzidi H, Ben Yahya S, Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res. 2012;84:378–83.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Deepika Garg
    • 1
    Email author
  • Richard Grazi
    • 1
  • Geralyn M. Lambert-Messerlian
    • 2
  • Zaher Merhi
    • 3
  1. 1.Department of Obstetrics and GynecologyMaimonides Medical CenterBrooklynUSA
  2. 2.Departments of Pathology and Obstetrics and Gynecology, Women and Infants Hospital, AlpertMedical School at Brown UniversityProvidenceUSA
  3. 3.Department of Obstetrics and GynecologyNYU School of MedicineNew YorkUSA

Personalised recommendations